Beatriz Honorato
Overview
Explore the profile of Beatriz Honorato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez J, Zarate R, Bandres E, Boni V, Hernandez A, Sola J, et al.
Eur J Cancer
. 2012 Feb;
48(12):1774-80.
PMID: 22305465
Background: The immunoglobulin G1 (IgG(1)) monoclonal antibody (MoAb) Cetuximab is active in metastatic colorectal cancer (mCRC) as first or subsequent lines of therapy. Efficacy seems restricted to KRAS wild-type tumours....
2.
Salgado J, Honorato B, Garcia-Foncillas J
Clin Med Oncol
. 2011 Sep;
2:199-207.
PMID: 21892280
Mitochondria play important roles in cellular energy metabolism, free radical generation, and apoptosis. Mitochondrial DNA has been proposed to be involved in carcinogenesis because of its high susceptibility to mutations...
3.
Honorato B, Alcalde J, Martinez-Monge R, Zabalegui N, Garcia-Foncillas J
Gene Regul Syst Bio
. 2009 Sep;
2:63-70.
PMID: 19787075
Resistance to radio and chemotherapy is one of the major drawbacks in the progression of head and neck squamous cell cancer (HNSCC) patients, evidencing the importance of finding optimum molecular...
4.
Bandres E, Malumbres R, Cubedo E, Honorato B, Zarate R, Labarga A, et al.
Oncol Rep
. 2007 Mar;
17(5):1089-94.
PMID: 17390049
The benefit of postoperative adjuvant chemotherapy in patients with Dukes' B colorectal cancer is still uncertain and its routine use is not recommended. The five-year relapse rate is approximately 25-40%...
5.
Bandres E, Barricarte R, Cantero C, Honorato B, Malumbres R, Zarate R, et al.
Oral Oncol
. 2006 Nov;
43(7):713-9.
PMID: 17112774
EGFR overexpression has been implicated in the development of head and neck squamous cell carcinoma (HNSCC). This study evaluates the prognostic ability of four polymorphisms in EGFR gene for patients...
6.
Sanchez D, Rosell D, Honorato B, Lopez J, Arocena J, Sanz G
BJU Int
. 2006 Oct;
98(6):1320-5.
PMID: 17034507
Objective: To study human androgen receptor (hAR) mutations and their relationship to the clinical and pathological characteristics of patients with prostate cancer, as the mechanisms by which tumour cells escape...
7.
Bandres E, Malumbres R, Escalada A, Cubedo E, Gonzalez I, Honorato B, et al.
J Pediatr Hematol Oncol
. 2005 Oct;
27(10):537-42.
PMID: 16217257
The t(11;22)(q24;q12) translocation is present in up to 95% of Ewing tumor patients and results in the formation of an EWS-FLI-1 fusion gene that encodes a chimeric transcription factor. Many...
8.
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression
Bandres E, Andion E, Escalada A, Honorato B, Catalan V, Cubedo E, et al.
J Neurooncol
. 2005 Jun;
73(3):189-98.
PMID: 15980968
Chemotherapy with the alkylating agent BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea) is the most commonly used chemotherapeutic agent for gliomas. However, the usefulness of this agent is limited because tumor cell resistance to...
9.
Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, Cordeu L, et al.
Oncol Rep
. 2004 Jul;
12(2):287-92.
PMID: 15254690
The purpose of this study was to define gene expression profile changes in colorectal tumors in order to identify target genes involved in neoplastic progression. cDNA microarray analysis was used...